trending Market Intelligence /marketintelligence/en/news-insights/trending/h6-jT5jtIbJXCyaI6fExUg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Exicure raises $63.3M via capital offering to fund drug pipeline

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Exicure raises $63.3M via capital offering to fund drug pipeline

Exicure Inc. raised gross proceeds of about $63.3 million from a public offering of its common stock.

The Skokie, Ill.-based pharmaceutical company sold 31,625,000 common shares, including 4,125,000 shares sold as part of the underwriters' option to purchase additional shares.

Exicure, which specializes in gene regulatory and immunotherapeutic drugs, plans to utilize the net proceeds from the offering to advance cancer therapy AST-008 through a phase 1b/2 clinical trial and to develop a potential drug based on spherical nucleic acids for a neurology condition. The rest of the proceeds will be used for general corporate purposes.

Guggenheim Securities was the sole book-running manager. H.C. Wainwright & Co. and Ladenburg Thalmann were the co-managers, and Chardan was the lead manager for the offering.